Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P34096
UPID:
RNAS4_HUMAN
Alternative names:
-
Alternative UPACC:
P34096
Background:
Ribonuclease 4, with its unique ability to cleave after uridine bases, plays a crucial role in RNA metabolism. Its antimicrobial activity against uropathogenic E. coli highlights its importance in maintaining urinary tract sterility.
Therapeutic significance:
Understanding the role of Ribonuclease 4 could open doors to potential therapeutic strategies. Its antimicrobial properties suggest a promising avenue for addressing urinary tract infections.